VDR Activation and Uremic Cardiopathy: Myths and Paradoxes
Nephrology @ Point of Care · 2015
DOI: 10.5301/napoc.2015.14615 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nephrology @ Point of Care, 2015. Verfasst von Diego Brancaccio. Die Arbeit nennt 15 Literaturangaben.
Abstract (Originalsprache)
The role of vitamin D receptor (VDR) activators for the control of secondary hyperparathyroidism has been clarified during the last few decades; however, their possible activity in conditioning cardiovascular comorbidity and mortality has become of interest more recently. On the basis of experimental studies showing that VDR activating therapy is associated with a reduction of cardiac hypertrophy, the PRIMO Study (an international randomized controlled trial [RCT]) was carried out a few years ago, but the results were disappointing, as the group of uremic patients on dialysis treated for 48 weeks with paricalcitol showed no differences in comparison with controls in terms of regression of heart hypertrophy. The aim of this editorial is to analyze the possible reasons for such results, and to help understand the actual role of VDR activators in dialysis patients in controlling cardiovascular morbidity and mortality.
Zitieren
APA
Brancaccio, D. (2015). VDR Activation and Uremic Cardiopathy: Myths and Paradoxes. Nephrology @ Point of Care. https://doi.org/10.5301/napoc.2015.14615
Vancouver
Brancaccio D. VDR Activation and Uremic Cardiopathy: Myths and Paradoxes. Nephrology @ Point of Care. 2015. doi:10.5301/napoc.2015.14615
BibTeX
@article{Brancaccio2015,
author = {Brancaccio, Diego},
title = {VDR Activation and Uremic Cardiopathy: Myths and Paradoxes},
journal = {Nephrology @ Point of Care},
year = {2015},
doi = {10.5301/napoc.2015.14615}
}
EUVIMED